Q1 Earnings Forecast for Genmab A/S Issued By William Blair

Genmab A/S (NASDAQ:GMAB) – William Blair cut their Q1 2025 earnings estimates for shares of Genmab A/S in a research report issued on Monday, April 14th. William Blair analyst M. Phipps now expects that the company will earn $0.17 per share for the quarter, down from their prior forecast of $0.28. William Blair has a “Outperform” rating on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share.

Several other research firms also recently issued reports on GMAB. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research note on Thursday, February 13th. Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Sanford C. Bernstein downgraded shares of Genmab A/S from a “market perform” rating to an “underperform” rating in a research note on Tuesday, April 1st. BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. Finally, Truist Financial lowered their target price on Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $39.17.

Genmab A/S Stock Up 2.5 %

Shares of GMAB opened at $20.04 on Wednesday. The business has a 50-day simple moving average of $20.52 and a two-hundred day simple moving average of $21.20. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $30.41. The stock has a market cap of $13.26 billion, a PE ratio of 11.52, a PEG ratio of 2.65 and a beta of 1.07.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%.

Institutional Trading of Genmab A/S

A number of large investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC boosted its position in shares of Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after purchasing an additional 939 shares in the last quarter. Lindbrook Capital LLC boosted its holdings in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after buying an additional 950 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after buying an additional 1,051 shares during the period. Barclays PLC increased its stake in shares of Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock valued at $52,000 after acquiring an additional 2,285 shares in the last quarter. Finally, Cromwell Holdings LLC lifted its position in shares of Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after acquiring an additional 2,496 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.